

## OTCQB Certification

I, Ola Soderquist, Chief Financial Officer of Bioxytran, Inc. (“the Company”), certify that:

1. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (mark the box below that applies with an “X”):

**REGISTERED or REPORTING WITH THE SEC:**

- Company is registered under Section 12(g) of the Exchange Act  
 Company is reporting under Section 15(d) of the Exchange Act  
 Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act  
 Company is reporting under Regulation A (Tier 2)  
 Other (describe) \_\_\_\_\_

**EXEMPT FROM SEC REGISTRATION/NO SEC REPORTING OBLIGATIONS:**

- Company is exempt from registration under Exchange Act Rule 12g3-2(b)  
 Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator  
 Company is reporting under the Alternative Reporting Company Disclosure Guidelines and is otherwise exempt from registration and not required to file periodic reporting

2. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC’s EDGAR system or the OTC Disclosure & News Service, as applicable.
3. The company is duly organized, validly existing and in good standing under the laws of Nevada in which the Company is organized or does business.
4. The share information below is for the primary OTCQB traded security as of the latest practicable date:

US Trading Symbol		<u>BIXT</u>	<u>As of (date):</u>
Shares Authorized	(A)	<u>300,000,000</u>	<u>12/31/2023</u>
Total Shares Outstanding	(B)	<u>145,642,333</u>	<u>12/31/2023</u>
Number of Restricted Shares <sup>1</sup>	(C)	<u>115,986,088</u>	<u>12/31/2023</u>
Unrestricted Shares Held by Officers, Directors, 10% Control Persons & Affiliates	(D)	<u>0</u>	<u>12/31/2023</u>
Public Float: <i>Subtract Lines C and D from Line B</i>	(E)	<u>29,656,249</u>	<u>12/31/2023</u>
% Public Float: <i>Line E Divided by Line B (as a %)</i> <sup>2</sup>	(F)	<u>17.0%</u>	<u>12/31/2023</u>
Number of Beneficial Shareholders of at least 100 shares <sup>3</sup>	(G)	<u>1,401</u>	<u>12/31/2023</u>

<sup>1</sup> Restricted Shares means securities that are subject to resale restrictions for any reason. Your transfer agent should be able to provide the total number of restricted securities.

<sup>2</sup> Public Float means the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a “10 percent Control Person”), or any Affiliates thereof, or any Family Members of officers, directors, and control persons. Family Member shall mean a Person’s spouse, parents, children, and siblings, whether by blood, marriage or adoption, or anyone residing in such Person’s home. OTCQB traded securities are required to have a freely traded public float of at least 10% of the shares outstanding unless an exemption applies.

<sup>3</sup> Beneficial Shareholder means any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security. OTCQB traded securities are required to have at least 50 beneficial shareholders unless an exemption applies.

5. Convertible Debt:

The following is a complete list of all promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities that were issued or outstanding at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification. **(If the note is no longer outstanding as of the current date, but was outstanding during the previously described timeframe, the note must still be disclosed in the table below.):**

Check this box if there were no promissory notes, convertible notes, or other convertible debt arrangements issued or outstanding at any point during this time period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) <sup>4</sup>	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion <sup>5</sup>	Name of Noteholder (entities must have individual with voting / investment control disclosed). <sup>6</sup>	Reason for Issuance (e.g., Loan, Services, etc.)
05/03/21*	1,165,000	963,814	04/30/24	the lesser of (i) \$.13 per share or (ii) 85% of the closing price of Any Qualified Financing	2,435,291	7,413,954	Walleye Opportunities Master Fund (William England)	Loan
05/03/21	1,000,000	1,159,945	04/30/24	the lesser of (i) \$.13 per share or (ii) 85% of the closing price of Any Qualified Financing	0	8,922,654	Pharmalectin Partners LLC (Patrick Imeson)	Loan
<b>Total Outstanding Balance:</b>		\$2,123,759		<b>Total Shares:</b>	16,336,608			

Use the space below to provide any additional details, including footnotes to the table above:

On 05/03/2023 Walleye Opportunities Master Fund repurchased three (3) notes from original note holders.

6. The following is a complete list of any law firm(s) and attorney(s) that acted as the Company's primary legal counsel in preparing its most recent annual report. **Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel.** (If no attorney assisted in putting together the disclosure, identify the person(s) who prepared the disclosure and their relationship to the company.) Please also identify any other attorney, if different than the primary legal counsel, that assisted the company during the prior fiscal year on any matter including but not limited to, preparation of disclosure, press releases, consulting services, corporate action or merger assistance, etc.

Witherspoon Brajcich Mcphee, PLLC, 601 W Main Ave #714, Spokane, WA 99201 – Corporate Counsel (Robert J. Burnett)

<sup>4</sup> The Outstanding Balance is to include accrued interest.

<sup>5</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

<sup>6</sup> International Reporting Companies may elect not to disclose the names of noteholders who are non-affiliates of the company. "Affiliate" is a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, an officer, a director, or a shareholder beneficially owning 10 percent or more of the Company's outstanding shares.

Clark+Elbing LLP, 101 Federal St. 15th Fl., Boston, MA – Patents (J. Cooper McDonald)  
 Potomac Law Group PLLC, 1717 Pennsylvania Ave. NW, Ste 1025, Washington, DC – Patents (David Boundy)

7. The following is a complete list of third-party providers, engaged by the Company, its officers, directors or controlling shareholders, at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification, to provide investor relations services, public relations services, marketing, brand awareness, consulting, stock promotion, or any other related services to the Company. **Please include the following items in this list: firm name, firm address, primary contact name and description of services provided.** If none, please state “None”.

WallachBeth LLC, Harborside Financial Center Plaza 5, 185 Hudson St. Ste 1410, Jersey City, NJ 07311 – Investment Banker (Doug Bantum)  
 Umov Marketing, 137 East 36 St. Unt 13B, New York, NY 10016 – Web development (Guy Platt)  
 Cashflow Heaven Inc. 375 East Nevada St. Ashland Oregon 97520 – Competitor research (Peter Schultz)  
 Crystal Research LLC 800 3rd Ave, 17th Fl. New York, NY 10022 – Research Analyst (Jeffrey Kraws)  
 Kevin Mayo, 406 Wacouta Street, unit 714, St. Paul, MN 55101 – BioTech Advisor  
 Pinnacle Accounting Group, North 1438 U.S. 89 Alternate, Farmington, UT 84025 – Auditor (Cory Hunter)  
 BF Borgers CPA PC, 5400 W Cedar Ave, Lakewood, CO 80226 – Auditor (Ben Borgers)  
 Latham BioPharm Group One Broadway, Broadway 14th Floor, Cambridge, MA 02142 – CRO (Georgia Sloboda)  
 Securities Transfer Corporation, 2901 Dallas Pkwy Suite 380, Plano, TX 75093 – Transfer Agent (Matt Smith)  
 ClearThink Capital, 210 W 77<sup>th</sup> St, New York, NY 10024 – Corporate Advisory (Brian Loper)  
 Vestec Securities, 11477 Olde Cabin Road Suite 310, St. Louis, MO 63141 – Brokerage Firm (Averell Satloff)  
 Strl BioSystems, 2055 Limestone Rd, Wilmington Delaware – Clinical Trial (Ravi Avasarala)  
 Dutchess Capital Group, 12555 High Bluff Drive, San Diego, CA – Corporate Advisory (Michael Novielli)  
 Grit Capital1 First Canadian Place, Toronto, ON CANADA M5X1H3 – Corporate Advisory (Jules Gagnon)  
 JKCRS LLC, 701 Tillery St, Unit 12-1260, Austin, TX 78702 – BioTech Advisor (Thomas Alumparambil)

8. Officers, Directors and 5% Control Persons:

The following is a complete list of Officers, Directors and 5% Control Persons (control persons are beneficial owners of five percent (5%) or more of any class of the issuer’s equity securities), including name, address, and number of shares owned. Preferred shares, options, warrants that can be converted into common shares within the next 60 days should be included in the shareholdings listed below. **If any of the beneficial shareholders are corporate entities, provide the name and address of the person(s) owning or controlling such corporate entities. If the corporate entity owning 5% or more does not have a person(s) owning or controlling it, provide a note explaining why. For nominee accounts owning 5% or more, provide the name of the 5% beneficial shareholder for this account. If there are no beneficial shareholders of 5% or more behind a nominee account, add a note confirming this.**

Name (First, Last)	Position/company affiliation (ex: CEO, 5% control person)	City and State (and Country if outside US)	Number of Shares Owned (list common, preferred, warrants and options separately)	Class of shares owned	Percentage of Class of Shares Owned (undiluted)
David Platt	CEO	Newton, MA	59,532,708	common	40.1%
Ola Soderquist	CFO	Boston, MA	19,585,300	common	13.4%
Michael Sheikh	CCO	Spokane, WA	8,800,000	common	5.5%
Anders Utter	Director	Stoneham, MA	607,621	common	0.4%

Dale Conaway	Director	Lithonia, GA	588,521	common	0.4%
Alan Hoberman	Director	Mechanicsville, PA	661,821	common	0.5%
Hana Chen-Walden	Director	Paris, France	347,800	common	0.3%

Use the space below to provide any additional details, including conversion terms of any class of the issuer's equity securities:

9. Certification:

Date: 3/13/2024

Name of Certifying CEO or CFO: Ola Soderquist

Title: CFO

Signature: /s/ Ola Soderquist

(Digital Signatures should appear as "/s/ [OFFICER NAME]")